Loading...
•
Mar 31, 2021
Co-Diagnostics Q1 2021 Earnings Report
Reported strong quarterly results with revenue of $20.0 million, pre-tax income of $9.9 million, and diluted EPS of $0.26.
Key Takeaways
Co-Diagnostics reported a strong first quarter in 2021, with revenue reaching $20.0 million and diluted EPS of $0.26. The company is focused on developing rapid PCR diagnostic testing and expanding its product portfolio to meet global demand.
Delivered strong quarterly results following record results across 2020.
Saw great progress in the development of new rapid PCR diagnostic testing.
Maintained solid revenues, earnings, and free cash flow to start the year.
Accelerating investments in talent and the breadth of portfolio to create increased capacity and deliver sustained value.
Co-Diagnostics
Co-Diagnostics
Forward Guidance
Co-Diagnostics anticipates continued demand for its product portfolio amid strong market conditions.